Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 24:6:360.
doi: 10.1186/1752-1947-6-360.

Locally advanced breast cancer made amenable to radical surgery after a combination of systemic therapy and Mohs paste: two case reports

Tomoya Tsukada  1 , Tatsuo Nakano, Miki Matoba, Daisuke Matsui, Shozo Sasaki
Affiliations

Locally advanced breast cancer made amenable to radical surgery after a combination of systemic therapy and Mohs paste: two case reports

Tomoya Tsukada et al. J Med Case Rep. .

Abstract

Introduction: Chemotherapy and other systemic therapies are the primary treatments for patients with unresectable, locally advanced breast cancer. The clinical application of supportive care using Mohs paste has become widespread for the purpose of improving patients' quality of life. Here, we report two cases of locally advanced breast cancer, for which the patients underwent radical surgery after a combination of systemic therapy and Mohs chemosurgery.

Case presentations: Patient 1 was a 90-year-old Japanese woman with right breast cancer diagnosed as stage IIIB (T4bN1M0). The treatment included Mohs paste application and hormonal therapies. Patient 2 was a 60-year-old Japanese woman with right breast cancer diagnosed as stage IIIB (T4cN2aM0). Her treatment included Mohs paste application, together with chemotherapy (four cycles of 5-fluorouracil, epirubicin, and cyclophosphamide, and four cycles of docetaxel). In both cases, a reduction in the primary tumor volume was observed, and radical mastectomy and axillary lymph node dissection were possible without relaxation incision or skin flap.

Conclusion: We report patients with no distant metastases who were able to undergo radical resection after a combination of systemic therapy and Mohs chemosurgery. For locally advanced breast cancer, Mohs chemosurgery, in addition to multidisciplinary treatment, is useful.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Case 1.a: Macroscopic image of the right breast at the initial visit. b: Computed tomography (CT) findings at the initial visit. CT revealed a mass with overlying and surrounding skin thickening (arrowheads). c: Macroscopic image of the right breast before surgical treatment. d: CT findings before surgical treatment.
Figure 2
Figure 2
Case 2.a: Macroscopic image of the right breast at the initial visit. b: Computed tomography (CT) findings at the initial visit. CT revealed a mass with infiltration of the pectoralis major muscle (arrowheads). c: Macroscopic image of the right breast before surgical treatment. d: CT findings before surgical treatment.
See this image and copyright information in PMC

References

    1. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer guideline–version 2. Washington, USA: National Comprehensive Cancer Network; 2011.
    1. Schiech L. Malignant cutaneous wounds. Clin J Oncol Nurs. 2002;6:305–309. doi: 10.1188/02.CJON.305-309. - DOI - PubMed
    1. McDonald A, Lesage P. Palliative management of pressure ulcers and malignant wounds in patients with advanced illness. J Palliat Med. 2006;9:285–295. doi: 10.1089/jpm.2006.9.285. - DOI - PubMed
    1. Maida V, Ennis M, Kuziemsky C, Trozzolo L. Symptoms associated with malignant wounds: a prospective case series. J Pain Symptom Manage. 2009;37:206–211. doi: 10.1016/j.jpainsymman.2008.01.009. - DOI - PubMed
    1. Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, Steijlen PM, Vermeulen A, Neumann H, Kelleners-Smeets NW. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol. 2008;9:1149–1156. doi: 10.1016/S1470-2045(08)70260-2. - DOI - PubMed

LinkOut - more resources